BeiGene, Ltd.
BGNE
Hisse Senetlerindeki Sıralama
#1194
BeiGene, Ltd. is a global biotechnology enterprise that operates across the... BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
Hisse Fiyatı
$184.00
Son senkronizasyon: 2025-01-02
Piyasa Değeri
$19.28B
Değişim (1 gün)
-0.38%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret BeiGene, Ltd. (BGNE)
Kategori
Healthcare
BeiGene, Ltd. (BGNE) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 111.58M
BeiGene, Ltd. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 111.58M'dir. December 2023 sonunda şirketin 104.18M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
BeiGene, Ltd. (BGNE) için 2013 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 111.58M | 6.49% |
| 2024 | 104.78M | 0.58% |
| 2023 | 104.18M | 1.01% |
| 2022 | 103.13M | 11.15% |
| 2021 | 92.79M | 11.16% |
| 2020 | 83.47M | 38.99% |
| 2019 | 60.05M | 8.32% |
| 2018 | 55.44M | 32.69% |
| 2017 | 41.78M | 34.58% |
| 2016 | 31.05M | -1.49% |
| 2015 | 31.52M | -40.15% |
| 2014 | 52.66M | 0.00% |
| 2013 | 52.66M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | 127.56% |
US
|
|
| 396.00M | 254.92% |
US
|
|
| 478.91M | 329.23% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -44.27% |
NL
|
